Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

Antibiotic Korormicin A Kills Bacteria by Producing Reactive Oxygen Species.

Maynard A, Butler NL, Ito T, da Silva AJ, Murai M, Chen T, Koffas MAG, Miyoshi H, Barquera B.

J Bacteriol. 2019 May 8;201(11). pii: e00718-18. doi: 10.1128/JB.00718-18. Print 2019 Jun 1.

PMID:
30858300
2.

Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.

Chong PY, Shotwell JB, Miller J, Price DJ, Maynard A, Voitenleitner C, Mathis A, Williams S, Pouliot JJ, Creech K, Wang F, Fang J, Zhang H, Tai VW, Turner E, Kahler KM, Crosby R, Peat AJ.

J Med Chem. 2019 Apr 11;62(7):3254-3267. doi: 10.1021/acs.jmedchem.8b01719. Epub 2019 Mar 7.

3.

Immunization of Alpacas (Lama pacos) with Protein Antigens and Production of Antigen-specific Single Domain Antibodies.

Chow KM, Whiteheart SW, Smiley JR, Sharma S, Boaz K, Coleman MJ, Maynard A, Hersh LB, Vander Kooi CW.

J Vis Exp. 2019 Jan 26;(143). doi: 10.3791/58471.

PMID:
30741259
4.

Maya children working in the streets: Value mismatches from the village to the street setting.

Tovote KE, Maynard AE.

Int J Psychol. 2018 Dec;53 Suppl 2:34-43. doi: 10.1002/ijop.12556.

PMID:
30588623
5.

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.

Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.

6.

Transcriptomic responses to extreme low salinity among locally adapted populations of Olympia oyster (Ostrea lurida).

Maynard A, Bible JM, Pespeni MH, Sanford E, Evans TG.

Mol Ecol. 2018 Nov;27(21):4225-4240. doi: 10.1111/mec.14863. Epub 2018 Oct 5.

PMID:
30193406
7.

A reporting framework for describing and a typology for categorizing and analyzing the designs of health care pay for performance schemes.

Ogundeji YK, Sheldon TA, Maynard A.

BMC Health Serv Res. 2018 Sep 4;18(1):686. doi: 10.1186/s12913-018-3479-x.

8.

Are assumptions of consumer views impeding nano-based water treatment technologies?

Maynard AD, Kidd J.

Nat Nanotechnol. 2018 Aug;13(8):673-674. doi: 10.1038/s41565-018-0230-z. No abstract available.

PMID:
30082811
9.

Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome.

Tsai IC, McKnight K, McKinstry SU, Maynard AT, Tan PL, Golzio C, White CT, Price DJ, Davis EE, Amrine-Madsen H, Katsanis N.

Sci Rep. 2018 Jul 17;8(1):10779. doi: 10.1038/s41598-018-28709-y.

10.

Thinking Differently about Risk.

Maynard AD.

Astrobiology. 2018 Feb;18(2):244-245. doi: 10.1089/ast.2017.1774. Epub 2018 Jan 30. No abstract available.

PMID:
29381372
11.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

12.

Comparison of digital mammography and digital breast tomosynthesis in the detection of architectural distortion.

Dibble EH, Lourenco AP, Baird GL, Ward RC, Maynard AS, Mainiero MB.

Eur Radiol. 2018 Jan;28(1):3-10. doi: 10.1007/s00330-017-4968-8. Epub 2017 Jul 14.

PMID:
28710582
13.

Mitigating Risks to Pregnant Teens from Zika Virus.

Maynard AD, Bowman DM, Hodge JG Jr.

J Law Med Ethics. 2016 Dec;44(4):657-659. doi: 10.1177/1073110516684814.

PMID:
28661244
14.

Angioedema: Perioperative management.

Maynard AA, Burger CF, Schlesinger JJ.

SAGE Open Med Case Rep. 2017 Jun 8;5:2050313X17713912. doi: 10.1177/2050313X17713912. eCollection 2017.

15.

Redistribution and redesign in health care: An ebbing tide in England versus growing concerns in the United States.

Maynard A, Altman SH, Stearns SC.

Health Econ. 2017 Jun;26(6):687-690. doi: 10.1002/hec.3516. No abstract available.

PMID:
28470833
16.

Tiger on the prowl: Invasion history and spatio-temporal genetic structure of the Asian tiger mosquito Aedes albopictus (Skuse 1894) in the Indo-Pacific.

Maynard AJ, Ambrose L, Cooper RD, Chow WK, Davis JB, Muzari MO, van den Hurk AF, Hall-Mendelin S, Hasty JM, Burkot TR, Bangs MJ, Reimer LJ, Butafa C, Lobo NF, Syafruddin D, Maung Maung YN, Ahmad R, Beebe NW.

PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005546. doi: 10.1371/journal.pntd.0005546. eCollection 2017 Apr.

17.

Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.

Siefried KJ, Mao L, Kerr S, Cysique LA, Gates TM, McAllister J, Maynard A, de Wit J, Carr A; PAART study investigators.

PLoS One. 2017 Apr 3;12(4):e0174613. doi: 10.1371/journal.pone.0174613. eCollection 2017.

18.

Protein Corona-Induced Modification of Silver Nanoparticle Aggregation in Simulated Gastric Fluid.

Ault AP, Stark DI, Axson JL, Keeney JN, Maynard AD, Bergin IL, Philbert MA.

Environ Sci Nano. 2016 Dec 1;3(6):1510-1520. doi: 10.1039/C6EN00278A. Epub 2016 Nov 9.

19.

Shrinking the state: The fate of the NHS and social care.

Maynard A.

J R Soc Med. 2017 Feb;110(2):49-51. doi: 10.1177/0141076816686923. No abstract available.

PMID:
28169585
20.

Family Functioning Predicts Body Mass Index and Biochemical Levels of Youths with Nonalcoholic Fatty Liver Disease.

Smith JD, Montaño Z, Maynard A, Miloh T.

J Dev Behav Pediatr. 2017 Feb/Mar;38(2):155-160. doi: 10.1097/DBP.0000000000000379.

PMID:
27984419
21.

'Safe handling of nanotechnology' ten years on.

Maynard AD, Aitken RJ.

Nat Nanotechnol. 2016 Dec 6;11(12):998-1000. doi: 10.1038/nnano.2016.270. No abstract available.

PMID:
27920442
22.

Is nanotech failing casual learners?

Maynard AD.

Nat Nanotechnol. 2016 Sep 7;11(9):734-5. doi: 10.1038/nnano.2016.167. No abstract available.

PMID:
27599878
23.

Should the NHS abolish the purchaser-provider split?

Maynard A, Dixon M.

BMJ. 2016 Jul 12;354:i3825. doi: 10.1136/bmj.i3825. No abstract available.

PMID:
27406100
24.

Are we ready for spray-on carbon nanotubes?

Maynard AD.

Nat Nanotechnol. 2016 Jun 7;11(6):490-491. doi: 10.1038/nnano.2016.99. No abstract available.

PMID:
27272137
25.

Hospital Surgical Volumes and Mortality after Coronary Artery Bypass Grafting: Using International Comparisons to Determine a Safe Threshold.

Gutacker N, Bloor K, Cookson R, Gale CP, Maynard A, Pagano D, Pomar J, Bernal-Delgado E; as part of the ECHO collaboration.

Health Serv Res. 2017 Apr;52(2):863-878. doi: 10.1111/1475-6773.12508. Epub 2016 May 16.

26.

Exposure to Power-Frequency Magnetic Fields and the Risk of Infertility and Adverse Pregnancy Outcomes: Update on the Human Evidence and Recommendations for Future Study Designs.

Lewis RC, Hauser R, Maynard AD, Neitzel RL, Wang L, Kavet R, Meeker JD.

J Toxicol Environ Health B Crit Rev. 2016;19(1):29-45. doi: 10.1080/10937404.2015.1134370. Review.

27.

Navigating the risk landscape.

Maynard AD.

Nat Nanotechnol. 2016 Mar;11(3):211-2. doi: 10.1038/nnano.2016.28. No abstract available.

PMID:
26936813
28.

PERSONAL MEASURES OF POWER-FREQUENCY MAGNETIC FIELD EXPOSURE AMONG MEN FROM AN INFERTILITY CLINIC: DISTRIBUTION, TEMPORAL VARIABILITY AND CORRELATION WITH THEIR FEMALE PARTNERS' EXPOSURE.

Lewis RC, Hauser R, Maynard AD, Neitzel RL, Wang L, Kavet R, Morey P, Ford JB, Meeker JD; Earth Study Team.

Radiat Prot Dosimetry. 2016 Dec;172(4):401-408. doi: 10.1093/rpd/ncv515. Epub 2015 Dec 24.

29.

Navigating the fourth industrial revolution.

Maynard AD.

Nat Nanotechnol. 2015 Dec;10(12):1005-6. doi: 10.1038/nnano.2015.286. No abstract available.

PMID:
26632281
30.

Repeated dose (28-day) administration of silver nanoparticles of varied size and coating does not significantly alter the indigenous murine gut microbiome.

Wilding LA, Bassis CM, Walacavage K, Hashway S, Leroueil PR, Morishita M, Maynard AD, Philbert MA, Bergin IL.

Nanotoxicology. 2016;10(5):513-20. doi: 10.3109/17435390.2015.1078854. Epub 2015 Nov 2.

31.

Why we need risk innovation.

Maynard AD.

Nat Nanotechnol. 2015 Sep;10(9):730-1. doi: 10.1038/nnano.2015.196. No abstract available.

PMID:
26329105
32.

Rapid Kinetics of Size and pH-Dependent Dissolution and Aggregation of Silver Nanoparticles in Simulated Gastric Fluid.

Axson JL, Stark DI, Bondy AL, Capracotta SS, Maynard AD, Philbert MA, Bergin IL, Ault AP.

J Phys Chem C Nanomater Interfaces. 2015 Sep 3;119(35):20632-20641. doi: 10.1021/acs.jpcc.5b03634. Epub 2015 Jul 28.

33.

Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model.

Bergin IL, Wilding LA, Morishita M, Walacavage K, Ault AP, Axson JL, Stark DI, Hashway SA, Capracotta SS, Leroueil PR, Maynard AD, Philbert MA.

Nanotoxicology. 2016;10(3):352-60. doi: 10.3109/17435390.2015.1072588. Epub 2015 Aug 24.

34.

Quantifying, Visualizing, and Monitoring Lead Optimization.

Maynard AT, Roberts CD.

J Med Chem. 2016 May 12;59(9):4189-201. doi: 10.1021/acs.jmedchem.5b00948. Epub 2015 Aug 21.

PMID:
26262898
35.

The death of death rates?

Doran T, Bloor K, Maynard A.

BMJ. 2015 Jul 14;351:h3466. doi: 10.1136/bmj.h3466. No abstract available.

PMID:
26174623
36.

Learning from the past.

Maynard AD.

Nat Nanotechnol. 2015 Jun;10(6):482-3. doi: 10.1038/nnano.2015.120. No abstract available.

PMID:
26037835
37.

Put all GPs on a salaried contract.

Maynard A.

BMJ. 2015 Apr 30;350:h2254. doi: 10.1136/bmj.h2254. No abstract available.

PMID:
25929537
38.

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

Maynard A, Bloor K.

J R Soc Med. 2015 Jun;108(6):220-2. doi: 10.1177/0141076814568299. Epub 2015 Apr 28. No abstract available.

39.

Women in medicine: historical perspectives and recent trends.

Jefferson L, Bloor K, Maynard A.

Br Med Bull. 2015 Jun;114(1):5-15. doi: 10.1093/bmb/ldv007. Epub 2015 Mar 8.

PMID:
25755293
40.

The (nano) entrepreneur's dilemma.

Maynard AD.

Nat Nanotechnol. 2015 Mar;10(3):199-200. doi: 10.1038/nnano.2015.35. No abstract available.

PMID:
25740129
41.

Variations in health care delivery within the European Union.

Peiró S, Maynard A.

Eur J Public Health. 2015 Feb;25 Suppl 1:1-2. doi: 10.1093/eurpub/cku223. No abstract available.

PMID:
25690122
42.

Developmental effects of economic and educational change: cognitive representation in three generations across 43 years in a Maya community.

Maynard AE, Greenfield PM, Childs CP.

Int J Psychol. 2015 Feb;50(1):12-9. doi: 10.1002/ijop.12129. Epub 2015 Jan 14.

PMID:
25586310
43.

Could we 3D print an artificial mind?

Maynard AD.

Nat Nanotechnol. 2014 Dec;9(12):955-6. doi: 10.1038/nnano.2014.294. No abstract available.

PMID:
25466533
44.

Loss of Spatial Memory, Learning, and Motor Function During Normal Aging Is Accompanied by Changes in Brain Presenilin 1 and 2 Expression Levels.

Kaja S, Sumien N, Shah VV, Puthawala I, Maynard AN, Khullar N, Payne AJ, Forster MJ, Koulen P.

Mol Neurobiol. 2015 Aug;52(1):545-54. doi: 10.1007/s12035-014-8877-4. Epub 2014 Sep 10.

45.

Old materials, new challenges?

Maynard AD.

Nat Nanotechnol. 2014 Sep;9(9):658-9. doi: 10.1038/nnano.2014.196. No abstract available.

PMID:
25182032
46.

International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.

Lee IH, Bloor K, Hewitt C, Maynard A.

J Health Serv Res Policy. 2015 Jan;20(1):52-9. doi: 10.1177/1355819614545675. Epub 2014 Aug 4. Review.

47.

NHS England chief executive: welcome back, Simon. Here's your to-do list.

Appleby J, Charles A, Maynard A, Kar P, Gerada C, Prabhu U, O'Riordan D, Wood J, Alessi C, Doyle A, Dixon M, Kell S, Bell A, Dalton S, Rodrigues L, Coghill Y, Kline R, Morgan B, Farrington-Douglas J, Foster A, Humphries R, Keene S, Koczan P.

Health Serv J. 2014 Apr 4;124(6393):16-9. No abstract available.

PMID:
24956712
48.

Is novelty overrated?

Maynard AD.

Nat Nanotechnol. 2014 Jun;9(6):409-10. doi: 10.1038/nnano.2014.116. Review. No abstract available.

PMID:
24894473
49.

Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.

Tai VW, Garrido D, Price DJ, Maynard A, Pouliot JJ, Xiong Z, Seal JW 3rd, Creech KL, Kryn LH, Baughman TM, Peat AJ.

Bioorg Med Chem Lett. 2014 May 15;24(10):2288-94. doi: 10.1016/j.bmcl.2014.03.080. Epub 2014 Apr 3.

PMID:
24731273
50.

A decade of uncertainty.

Maynard AD.

Nat Nanotechnol. 2014 Mar;9(3):159-60. doi: 10.1038/nnano.2014.43. No abstract available.

PMID:
24594788

Supplemental Content

Loading ...
Support Center